| Gene symbol | CD276 | Synonyms | 4Ig-B7-H3, B7-H3, B7H3, B7RP-2 | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q24.1 | dbXrefs | |
| Description | CD276 molecule | ||||
| Gene symbol | ERBB2 | Synonyms | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | erb-b2 receptor tyrosine kinase 2 | ||||
| Gene symbol | FOLH1 | Synonyms | FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM, PSMA, mGCP | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p11.12 | dbXrefs | |
| Description | folate hydrolase 1 | ||||
| GTO ID | GTC2383 |
| Trial ID | NCT04433221 |
| Disease | Sarcoma | Ewing Sarcoma | Osteosarcoma |
| Altered gene | GD2|PSMA|HER2|CD276 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | GD2/PSMA/HER2/B7-H3 CAR-T cells |
| Co-treatment | sarcoma vaccines |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Combination Immunotherapy Targeting Sarcomas |
| Year | 2020 |
| Country | China |
| Company sponsor | Shenzhen Geno-Immune Medical Institute |
| Other ID(s) | GIMI-IRB-20007 |
| Cohort 1 | |||||||||||
|
|||||||||||